Latest news with #Hogan
The Journal
15 hours ago
- Health
- The Journal
Weight loss injections become more attainable as they enter beauty clinics
THE MOVE TO bring obesity treatment injections further into mainstream use has taken another step forward with the news that it's now being offered outside strictly medical settings. Thérapie Clinics, best known for lip fillers and laser hair removal treatments, has now launched the doctor-led service Thérapie Health to provide access to Wegovy obesity treatment injections in Ireland. The company says it is a 'medically managed programme for those who meet the correct criteria'. The move has been largely appreciated by experts and patients who are advocating for increased accessibility to the medication to prevent people looking towards the black market. According to the HSE, Ireland has one of the highest levels of obesity in Europe , with 60% of adults living with the disease. Obesity treatment injections are intended to fight obesity and its associated diseases, such as type 2 diabetes, cardiovascular disease, respiratory disease, several types of cancer, pain and musculoskeletal disorders. It costs €365 to begin using obesity treatment injections at Thérapie Health, including €220 per month for the Wegovy medication. Each follow-up appointment costs €35. Belinda Hogan, who lost over 80 pounds using Ozempic between 2022 and 2023, told The Journal she welcomes an increase in the availability of the obesity treatment injections. 'I would say it's a good thing because if you get to go in and sit in front of a doctor, they can check your health markers,' she said. She highlighted the importance of doctors being knowledgeable about the medications and clearly communicating the administration process to patients. Advertisement Hogan runs an online coaching programme for users of weight loss injections, she said she receives messages every day from people who have been prescribed the medication but don't know how to use it. She also said cost can be a barrier to accessing obesity treatment injections. 'It's wealthcare as opposed to healthcare. It's not fair,' she said. 'It doesn't just help you lose weight, it staves off other health medications. It stopped me getting diabetes, and being an absolute drain on the system,' she added. Hogan uses an online doctor service based in Northern Ireland to access her prescription to Mounjaro, as the medication is cheaper in the North. Mounjaro medication generally ranges from €285 to €475 per month in pharmacies in the Republic of Ireland, in comparison to £133.40 (€153.94) to £254.91 (€294.06) per month in pharmacies in Northern Ireland. Aisling O'Leary lost over 100 pounds using Ozempic between 2022 and 2023. She said: 'I'm a huge advocate for these medications to be used for treatment of chronic obesity, but it is a disease, and it should be done right through the correct channels.' 'People need to be making monthly check-ups, but also need to be referred to a dietician and counsellor to treat all parts of the obesity disease, not just take the medication and hope for the best,' she added. O'Leary, who is a medical card holder, paid €139.50 monthly for Ozempic during her weight loss journey, which took a considerable chunk out of her income as a pensioner. She said the medication should be available on the drug payment scheme, adding that many people travel to Northern Ireland to access Mounjaro. Dr Francis Finucane, Consultant Endocrinologist with the National Clinical Programme for Obesity, told The Journal he welcomes the move by Thérapie. Read Next Related Reads Will Ireland follow the UK with free Mounjaro jabs? Minister says assessment to be ready by next year He said: 'It appears to be a bona fide clinically supervised doctor service with carefully considered criteria'. Dr Finucane said the cost of the drugs act as a barrier for people who could benefit from their use and criticised the lack of funding for obesity treatment medication in Ireland. Weight loss injections in Ireland currently cost between €120 and €475 per month. He said: 'They are extremely expensive considering they are being used for legitimate a disease.' 'The Health Service will not fund effective proven treatment of disease', he said, adding that services relating to diseases from alcohol and smoking are funded 'generously and compassionately' by the state. Minister for Health Carroll MacNeill said that Wegovy will be available as early as the end of 2025 as part of the HSE's reimbursement schemes, including the Medical Card Scheme and Drugs Payment Scheme. Another weight loss injection, Saxenda, has been available on the scheme since January 2023. Dr Finucane warned that caution must be exercised when accessing obesity treatment injections. 'There are unscrupulous actors out there using these drugs for cosmetics, gaining financially from vulnerable people who want to be skinny,' he said. He said that in some cases obesity treatment injections are not being used for their intention of fighting obesity and the connected health issues, but rather as a cosmetic enhancement to fulfil the 'cultural desire for thinness'. According to Dr Finucane, the aesthetical desire to be thin 'mopped up the demand for the medication', in part contributing to the shortage of these medications in 2023. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Daily Mirror
21 hours ago
- Entertainment
- Daily Mirror
Kenneth Washington dead: Star Trek actor dies as tributes paid
Actor Kenneth Washington died, aged 89, last week, it's been announced. He had a decades-long career in the industry, which including making appearances in shows like Star Trek and he had a starring role on Hogan's Heroes.
Business Times
2 days ago
- Business
- Business Times
US: Nasdaq ends six-day streak of records
[NEW YORK] The Nasdaq retreated from a record Tuesday on a mixed day for stocks as markets looked ahead to upcoming earnings reports from Google parent Alphabet and Tesla. The two reports on Wednesday are the first of Wall Street's 'Magnificent Seven' equities to report this season. The group was mixed, with drops in Nvidia and other semiconductor equities consistent with profit taking after earlier gains, analysts said. The tech-rich Nasdaq fell 0.4 per cent to 20,892.69, snapping a six-day streak of record high finishes. But the broad-based S&P 500 edged up 0.1 per cent to 6,309.62, finishing at a record, while the Dow Jones Industrial Average climbed 0.4 per cent to 44,502.44. Art Hogan of B. Riley Wealth Management described the market as in a 'wait and see' mode ahead of earnings from the most influential equities. Stocks are priced for perfection, Hogan added. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up 'It's a difficult earnings season where expectations are really low but stocks are already priced very high,' he said. Among individual companies, General Motors dropped 8.1 per cent despite reporting better than expected quarterly earnings. While the automaker confirmed its full-year forecast, it said profitability in the second half of 2025 would lag the first part of the year, in part due to the increased impact of tariffs. Lockheed Martin was another big loser, shedding 10.8 per cent after its results were dented by around US$1.7 billion in one-time costs. But DR Horton surged 17 per cent after the homebuilder's results topped estimates. said the homebuilder's earnings outperformed competition, establishing it as 'a potential leader in navigating the challenging housing market.' AFP
Straits Times
2 days ago
- Business
- Straits Times
Nasdaq ends six-day streak of records
Find out what's new on ST website and app. Traders working on the floor of the New York Stock Exchange, in New York City. NEW YORK - The Nasdaq retreated from a record on July 22 on a mixed day for stocks as markets looked ahead to upcoming earnings reports from Google parent Alphabet and Tesla. The two reports on July 23 are the first of Wall Street's 'Magnificent Seven' equities to report this season. The group was mixed, with drops in Nvidia and other semiconductor equities consistent with profit taking after earlier gains, analysts said. The tech-rich Nasdaq fell 0.4 per cent to 20,892.69, snapping a six-day streak of record high finishes. But the broad-based S&P 500 edged up 0.1 per cent to 6,309.62, finishing at a record, while the Dow Jones Industrial Average climbed 0.4 per cent to 44,502.44. Mr Art Hogan, of B. Riley Wealth Management, described the market as in a 'wait and see' mode ahead of earnings from the most influential equities. Stocks are priced for perfection, Hogan added. 'It's a difficult earnings season where expectations are really low but stocks are already priced very high,' he said. Top stories Swipe. Select. Stay informed. Singapore Two found dead after fire in Toa Payoh flat Singapore Singaporeans aged 21 to 59 can claim $600 SG60 vouchers from July 22 Singapore Singaporeans continue to hold world's most powerful passport in latest ranking Singapore Singapore, Vietnam agree to step up defence ties, dialogue between leaders Asia Malaysia govt's reform pledge tested as DAP chief bows over unresolved 2009 death of political aide Tech Singapore to increase pool of early adopters in AI to complement data scientists, engineers Singapore Prosecution says judge who acquitted duo of bribing ex-LTA official had copied defence arguments Singapore Ports and planes: The 2 Singapore firms helping to keep the world moving Among individual companies, General Motors dropped 8.1 per cent despite reporting better than expected quarterly earnings. While the automaker confirmed its full-year forecast, it said profitability in the second half of 2025 would lag the first part of the year, in part due to the increased impact of tariffs. Lockheed Martin was another big loser, shedding 10.8 per cent after its results were dented by around US$1.7 billion (S$2.1 billion) in one-time costs. But DR Horton surged 17 per cent after the homebuilder's results topped estimates. said the homebuilder's earnings outperformed competition, establishing it as 'a potential leader in navigating the challenging housing market.' AFP
RTHK
2 days ago
- Business
- RTHK
Nasdaq ends six-day streak of records
Nasdaq ends six-day streak of records The S&P 500 inched to another record on Tuesday following some mixed profit reports, while the Nasdaq slipped 0.4 percent. Photo: Reuters The Nasdaq retreated from a record on Tuesday on a mixed day for stocks as markets looked ahead to upcoming earnings reports from Google parent Alphabet and Tesla. The two reports on Wednesday are the first of Wall Street's "Magnificent Seven" equities to report this season. The group was mixed, with drops in Nvidia and other semiconductor equities consistent with profit taking after earlier gains, analysts said. The Nasdaq fell 0.4 percent to 20,892, snapping a six-day streak of record high finishes. But the S&P 500 edged up 0.1 percent to 6,309, finishing at a record, while the Dow Jones climbed 0.4 percent to 44,502. Art Hogan of B Riley Wealth Management described the market as in a "wait and see" mode ahead of earnings from the most influential equities. Stocks are priced for perfection, Hogan added. "It's a difficult earnings season where expectations are really low but stocks are already priced very high," he said. Among individual companies, General Motors dropped 8.1 percent despite reporting better than expected quarterly earnings. While the automaker confirmed its full-year forecast, it said profitability in the second half of 2025 would lag the first part of the year, in part due to the increased impact of tariffs. Lockheed Martin was another big loser, shedding 10.8 percent after its results were dented by around US$1.7 billion in one-time costs. But DR Horton surged 17 percent after the homebuilder's results topped estimates. said the homebuilder's earnings outperformed competition, establishing it as "a potential leader in navigating the challenging housing market." (AFP)
